Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bortezomib + IGEV
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
Bortezomib + IGEV is a combination chemotherapy regimen used primarily in the treatment of relapsed or refractory Hodgkin lymphoma. The regimen consists of bortezomib (a proteasome inhibitor) added to the standard IGEV protocol, which includes ifosfamide, gemcitabine, vinorelbine, and prednisone. Bortezomib acts by reversibly inhibiting the 26S proteasome in cells, leading to cell cycle arrest and apoptosis of cancer cells. The addition of bortezomib to IGEV has been studied for its potential to improve outcomes prior to high-dose chemotherapy and autologous stem cell transplantation in patients with Hodgkin lymphoma who have not responded adequately to previous treatments[1][2]. Clinical studies indicate that while toxicity is similar between regimens with or without bortezomib, adding it does not significantly improve response rates but maintains a favorable safety profile[2].
- Other names
- bortezomib plus IGEVbortezomib + ifosfamide + gemcitabine + vinorelbine + prednisone
02
Targets
GR (Glucocorticoid receptor)MicrotubulePSMB5 (Proteasome subunit beta Type-5)TUBA (Tubulin alpha/beta dimer)
Beyond the preview
Go deeper on bortezomib + IGEV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bortezomib + IGEV.